Jefferies upgraded PeptiDream to Buy from Hold with a price target of 1,600 yen, down from 1,900 yen. The analyst says the company seems likely to book a strong Q3 on the back of milestone and upfront payments from Merck, Astellas and Genentech.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>